COVID-19, gender and estroprogestins, what do we know?
Fidecicchi, Tiziana ![Identificador ORCID](/img/uab/orcid.ico)
(Department of Obstetrics and Gynecology. Pisa University Hospital of S. Chiara. Azienda Ospedaliera Universitaria)
Fruzzetti, Franca ![Identificador ORCID](/img/uab/orcid.ico)
(Department of Obstetrics and Gynecology. Pisa University Hospital of S. Chiara. Azienda Ospedaliera Universitaria)
Lete Lasa, Luis Ignacio ![Identificador ORCID](/img/uab/orcid.ico)
(Department of Obstetrics and Gynaecology. Araba University Hospital)
Calaf Alsina, Joaquim ![Identificador ORCID](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona
Data: |
2022 |
Resum: |
The new coronavirus disease-19 (COVID-19) pandemic has rapidly spread all around the world, eliciting many questions and doubts about the pathogenesis of the disease and treatment. Mortality has been related to a prothrombotic state. Risk factors for the infection and for severe forms of COVID-19 have still to be defined. According to data collected, women appear to be less prone to severe forms of the disease and their mortality was lower than for men. The role of female hormones in the modulation of inflammation may be the reason behind this gender gap. Considering the prothrombotic state activated by the virus, hormone therapies have been placed under investigation as possible increasing risk factors for severe forms. Moreover, new vaccines and their rare thrombotic side effects have increased the concern about this issue. The goal of this review is to go over the mechanisms that lead up to thrombosis during COVID-19, trying to explain the possible reasons why women seem to be naturally protected. The expert opinions about whether to continue/discontinue hormonal therapies are reviewed. Moreover, available data about the so-called 'vaccine induced immune thrombotic thrombocytopaenia' caused by vaccines against COVID-19 are discussed. |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ![Creative Commons](/img/licenses/by-nc-nd.ico) |
Llengua: |
Anglès |
Document: |
Article de revisió ; recerca ; Versió publicada |
Matèria: |
SARS-CoV2 ;
Inflammation ;
Cytokine storm ;
Combinedhormonal contraceptives ;
Vaccine-induced immunethromboticthrombocytopenia |
Publicat a: |
European Journal of Contraception and Reproductive Health Care, Vol. 27 Núm. 1 (2022) , p. 67-74, ISSN 1473-0782 |
DOI: 10.1080/13625187.2021.2000959
PMID: 34842025
El registre apareix a les col·leccions:
Documents de recerca >
Documents dels grups de recerca de la UAB >
Centres i grups de recerca (producció científica) >
Ciències de la salut i biociències >
Institut de Recerca Sant PauArticles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2023-07-19, darrera modificació el 2023-10-01